Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients
Nakazono, Y.; Abe, H.; Murakami, H.; Koyabu, N.; Isaka, Y.; Nemoto, Y.; Murata, S.; Tsutsumi, Y.; Ohtani, H.; Sawada, Y.
International Journal of Clinical Pharmacology and Therapeutics 43(4): 163-171
2005
ISSN/ISBN: 0946-1965 PMID: 15966462 Document Number: 586453
The aim of the present study is to examine the relationship between dopamine D-2-receptor gene (DRD2) polymorphisms (Taq1A, Taq1B, -141C Ins/Del) and the risk of extrapyramidal adverse effects (EPS), assessed according to the Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), or the maintenance dose of anti-psychotics in schizophrenic patients. The DIEPSS score was significantly higher in patients bearing the -141C Del allele than in those without it. Taq1A and Taq1B restriction fragment length polymorphisms (RFLPs) did not significantly affect the DIEPSS score. On the other hand, maintenance doses of neuroleptics and antiparkinsonian drugs were significantly higher in patients with the B1 allele of Taq1B RFLP than in those without it, while the Taq1A RFLP and -141C Ins/Del polymorphisms were not significantly related to the maintenance doses. In conclusion, the risk of EPS may be increased in patients with the -141C Del allele of the DRD2 gene. In these patients, antipsychotics should be administered with caution.